Pro Medicus Ltd (PME) shares jump 5% on report

Melbourne-based Pro Medicus Ltd (ASX:PME) shares were trading 5% higher on Thursday following the release of its 2020 half-year financial report.

For context, the broader Australian share market or S&P/ASX 200 (ASX: XJO) was trading at 7141.4, up 0.75%.

About Pro Medicus

Pro Medicus is a Melbourne-based software owner and developer, licensing products to large US hospitals and Australian radiology clinics. The company has offices in Richmond, Victoria, Berlin, Germany and in the United States.

In the Rask video above, Owen explains how analysts read an annual report quickly, including the 7 pieces of information to look for. You can take one of Owen’s free finance courses by clicking here.

Key Results

This period Last period Change
Revenue 29.3 25.31 15.76%
Profit 12.05 9.08 32.71%
Operating cash flow 16.14 6.4 152.19%
Dividends 6 cents 3.5 cents 71.43%

Source: Pro Medicus Ltd announcements; author calculations, AUD million unless otherwise stated. 

As can be seen above, the company’s revenue came in at $29.3 million, up $4 million. However, that figured included a once-off capital purchase last year.

Pro Medicus’ profit was $12.05 million for the period, up $2.97 million. On the cash flow statement, which is an important financial statement since it represents the underlying health of a business, operating free cash flow was $16.14 million, up $9.74 million. This was boosted by the payment of an outstanding trade receivable.

Finally, dividends declared by the company were 6 cents per share, up 71%.

The company said it was able to deliver underlying revenue growth across each key market segment, including America (43%), Europe (52%) and Australia (21%). Two of the key contracts the company won in the period were the Ohio State University Wexler Medical Center, for $9 million over 5 years, and with Nines Inc, a teleradiology platform, for $6 million over five years.

“All our numbers moved in the right direction,” Co-founder and CEO Dr. Sam Hupert said.

“If you exclude the one off capital sale in HY19 the underlying revenue growth figure is 39.1%. We were able to achieve this as a result of the significant step-up in our transaction revenue which grew by 30% compared to the previous 6 month period.”

Pro Medicus increased its cash reserves by over 20%, Dr. Hupert noted, while also buying back shares and increasing tax payments.

Finally, Dr. Hupert said the company’s implementation team once again proved its ability to deliver installs in record time, and the leads from new clients appear to be stronger than ever.

“There is no doubt we are experiencing an increased network effect generated by our growing customer base in North America, not just in the Tier 1 academic space but also other segments of the market as witnessed by the recent Nines contract.”

For a more detailed analysis of Pro Medicus, you can go to A Rich Life.

Pro Medicus shares were last seen trading around $28.70, giving the company a market capitalisation around $3 billion.

Free report: 3 cloud stocks to buy now

As we emerge from COVID-19, some tech companies are growing faster than ever. Rask’s investment analysts have identified 3 growth stocks set to benefit. Big time.

We’ll send you our report for free, including the names, ticker codes and analysis when you enter your email address below.

Unsubscribe anytime. Read our TermsFinancial Services GuidePrivacy Policy. We’ll never sell your email address. Our company is Australian owned.

Free report: 3 cloud stocks to buy now

As we emerge from COVID-19, some tech companies are growing faster than ever. Rask’s investment analysts have identified 3 growth stocks set to benefit. Big time.

Click here to access this report for free, including the names, ticker codes and analysis.

Information warning: The information on this website is published by The Rask Group Pty Ltd (ABN: 36 622 810 995) is limited to factual information or (at most) general financial advice only. That means, the information and advice does not take into account your objectives, financial situation or needs. It is not specific to you, your needs, goals or objectives. Because of that, you should consider if the advice is appropriate to you and your needs, before acting on the information. If you don’t know what your needs are, you should consult a trusted and licensed financial adviser who can provide you with personal financial product advice. In addition, you should obtain and read the product disclosure statement (PDS) before making a decision to acquire a financial product. Please read our Terms and Conditions and Financial Services Guide before using this website. The Rask Group Pty Ltd is a Corporate Authorised Representative (#1280930) of AFSL #383169.

Keep reading: